ReviewNature reviews. Clinical oncology2012
Molecular prescreening to select patient population in early clinical trials.
Review in Nature reviews. Clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Trial
- Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.British journal of cancer · 2014Trial
- Transcriptomics analysis unveils the complex interplay between diabetes and hypertension in regulating renal cell carcinoma pathway followed by pancreatic metastasis.Journal, genetic engineering & biotechnology · 2025Article
- First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.Frontiers in oncology · 2021Article
- Ciliary Genes in Renal Cystic Diseases.Cells · 2020Review
- Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials.JCO precision oncology · 2020Article
- Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics.Histopathology · 2019Review
- New clinical trial designs in the era of precision medicine.Molecular oncology · 2019Review
- Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015.Investigational new drugs · 2019Review
- Review
- Evaluating Clinical Genome Sequence Analysis by Watson for Genomics.Frontiers in medicine · 2018Article
- Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.ESMO open · 2018Article
- Cancer Immunotherapy, Part 3: Challenges and Future Trends.P & T : a peer-reviewed journal for formulary management · 2017Article
- Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.Neuro-oncology · 2017Article
- Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.JMIR research protocols · 2017Article
- New generation of breast cancer clinical trials implementing molecular profiling.Cancer biology & medicine · 2016Article
- Review
- The current use and attitudes towards tumor genome sequencing in breast cancer.Scientific reports · 2016Article
- The changing landscape of phase I trials in oncology.Nature reviews. Clinical oncology · 2016Review
- A framework for prescription in exercise-oncology research.Journal of cachexia, sarcopenia and muscle · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of targeted therapies in patient populations selected for treatment on the basis of the molecular features of their tumours is shifting the current focus of treatment to biomarker-driven clinical trials. Phase I trials provide an arena for early hypothesis testing, examining not only safety and toxicity, but also target engagement, biologically effective dosages, and the appropriate patient population. In this Perspectives article, we describe this new trend in early drug development, establishing the different approaches for building a pre-screening programme in an academic institution that is involved in early drug development. Our experience establishing the phase I programme at Vall d'Hebrón serves as an example of how these approaches can be integrated in ongoing trials, and we believe these considerations will help others to implement similar programmes in their institutions.
Indexed as
Identifiers
22473105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.